Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Список исп. литературыСкрыть список 1. Bartus RT, Dean RL, Beer B et al. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217 (4558): 408–14. 2. Whitehouse PJ, Price DL, Struble RG et al. Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science 1982; 215 (4537): 1237–9. 3. Cummings JL. Cholinesterase Inhibitors: A New Class of Psychotropic Compounds. Am J Psychiat 2000; 1: 4–15. 4. Kumar V. Clinical pharmacology of tetrahydroaminoacridine: a possible therapeutic agent for Alzheimer's disease. Int J Clin Pharmacol Toxicol 1989; 27 (10): 478–85. 5. Ritchie CW, Ames D, Clayton T et al. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriat Psychiat 2004; 12: 358–69. 6. Holmes C, Wilkinson D, Dean C et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004; 63: 214–9. 7. Aupperle PM, Koumaras B, Chen M et al. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer’s disease: results of a 52-week open-label study. Curr Med Res Opin 2004; 20: 1605–12. 8. Sevilla C, Jimenez Caballero PE, Alfonso V et al. Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients? Dement Geriat Cogn Dis 2009; 28: 196–205. 9. Shua-Haim J, Smith J, Picard F et al. Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer’s disease not affected by coadministration of memantine: an open-label, crossover, single-centre study. Clin Drug Investig 2008; 28: 361–74. 10. Приказ Минздрава СССР от 11.06.1990 г. №230 «О разрешении к медицинскому применению». 11. Электронный источник: http://pikfarma.ru/production/32 12. McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS/ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34 (7): 939–44. 13. Roman GС, Tatemichi TK, Erkinjuntti T et al. Neurology. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS/AIREN International Workshop 1993; 43 (2): 250–60. 14. Winblad B et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease – rivastigmine patch vs. capsule. Int J Geriat Psychiat 2007; 22: 456–67. 15. Emre M et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004; 351 (24): 2509–18. 16. Guekht AB, Moessler H, Novak PH, Gusev EI. Церебролизин при сосудистой деменции. Междунар. неврол. журн. 2011; 1: 39.